Peripheral opioid antagonists: a therapeutic advance for optimizing opioid gastrointestinal tolerability.
Fakata
Keri L
KL
College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
Cole
B Eliot
BE
D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D002400:Cathartics / Q000627:therapeutic use*; D003248:Constipation / Q000139:chemically induced* / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004502:Education, Medical, Continuing; D005194:Family Practice / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D015994:Incidence; D008297:Male; D020714:Maximum Tolerated Dose; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D010148:Intractable Pain / Q000175:diagnosis / Q000188:drug therapy; D018570:Risk Assessment; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D002400:Cathartics; D009292:Narcotic Antagonists